Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan

Lin, Chen; Chang, Jeffrey S.; Huang, Shih Ming; Hung, Chung Jye; Hung, Chien Ling; Chang, Chiz Tzung; Yang, Horng Ren; Hsieh, Te Chun; Huang, Yu Hui Jenny; Tsai, Hung-Pei

doi:10.1016/j.jfma.2020.04.021

Cited by 14 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, we could not classify the patients according to individual prognostic factors, including the American Joint Committee on Cancer staging system and the ATA risk stratification system. However, above 95% of thyroid cancer cases in Taiwan are diagnosed as differentiated thyroid cancer at the localized stage [33][34][35]. Our study matched the gender and age in the study (RAI) and control (non-RAI) groups and focused on the impact of RAI cumulative dose on the risk of long-term CVD morbidity and mortality.…”

Section: Discussionmentioning

confidence: 99%

Radioactive Iodine Treatment and the Risk of Long-Term Cardiovascular Morbidity and Mortality in Thyroid Cancer Patients: A Nationwide Cohort Study

Kao

Chung

Chien

et al. 2021

JCM

View full text Add to dashboard Cite

(1) Background: This study aimed to investigate the association between radioactive iodine (RAI) and long-term cardiovascular disease (CVD) morbidity/mortality in thyroid cancer. (2) Methods: The study was conducted using data from the Taiwan National Health Insurance Database during 2000–2015. Thyroid cancer patients aged ≥20 years were categorized into RAI (thyroidectomy with RAI) and non-RAI (thyroidectomy only) groups. The Cox proportional hazard regression model and Kaplan–Meier method were used for analysis. (3) Results: A total of 13,310 patients were included. Kaplan–Meier analysis demonstrated that the two groups had similar cumulative risks of CVD (log-rank p = 0.72) and CVD-specific mortality (log-rank p = 0.62). On Cox regression analysis of different RAI doses, the risk of CVD was higher in the cumulative dosage >3.7 GBq (hazard ratio = 1.69, 95% confidence interval = 1.24–2.40, p < 0.001). (4) Conclusions: RAI was not associated with an increased risk of CVD in thyroid cancer. However, CVD surveillance is indicated in the patients receiving the cumulative RAI dosage above 3.7 GBq.

show abstract

Section: Discussionmentioning

confidence: 99%

Radioactive Iodine Treatment and the Risk of Long-Term Cardiovascular Morbidity and Mortality in Thyroid Cancer Patients: A Nationwide Cohort Study

Kao

Chung

Chien

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…In fact, the evaluation of genetic mutations is applicable in the process of development of therapies targeting the production pathway [ 17 , 18 , 19 ]. In some studies, a better response rate to treatment has been observed in BARF+ patients, leading to the development of studies only for this category of patients [ 20 , 21 , 22 , 23 , 24 ]. So, even if we focus only on few patients, selecting their best personalized treatment option is important.…”

Section: Discussionmentioning

confidence: 99%

Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers

Piciu

Larg

Piciu

2020

JPM

View full text Add to dashboard Cite

In thyroid neoplastic pathology, the BRAF V600E mutation is shown to be involved in the oncogenesis of papillary thyroid cancer and its subtypes. The purpose of this study is to evaluate the correlation between the mutation of the BRAF V600E oncogene and the pathological standardized uptake values (SUV) at the F18-fluorodeoxyglucose (F18-FDG) positron emission tomography/computed tomography (PET/CT) evaluation, for a group of 20 patients with radically treated (total thyroidectomy and radioiodine therapy) papillary thyroid cancer, with subclinical persistent disease, at 6 months after the initial treatment. We analyzed the correlations between the values of SUV and the presence of the BRAF mutation as well with other prognostic factors such as stage, age, specific tumor markers (thyroglobulin and anti-thyroglobulin), extrathyroid extension, the presence of metastatic lymph nodes or distant metastasis. The value of SUV in the case of BRAF+ (positive) patients was higher than in the negative ones, but without statistical significance, thus, the values of the SUV cannot be a predictable factor for the presence of the genetic mutation. There was a statistically significant correlation in BRAF+ subgroup between the SUV values and the positive resection limit following surgery, showing a higher SUV value in the PET/CT evaluation. No correlation was observed between the aforementioned prognostic factors involved in papillary thyroid cancer and the BRAF V600E mutation.

show abstract

“…Sorafenib and bortezomib are two FDA-approved drugs that are each used to treat specific cancers. Sorafenib is a Raf1 / Mek / Erk kinase inhibitor used to treat hepatocellular carcinoma (Adjibade et al, 2015), thyroid carcinoma (Lin et al, 2021), and renal carcinoma (Chen W. et al, 2018). Remarkably, treatment with sorafenib induces phosphorylation of the eIF2 alpha subunit by PERK and increases the formation of SGs (Adjibade et al, 2015).…”

Section: Chemotherapy Resistancementioning

confidence: 99%

Stress Granules Involved in Formation, Progression and Metastasis of Cancer: A Scoping Review

Asadi

Rahmanpour

Moslehian

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

The assembly of stress granules (SGs) is a well-known cellular strategy for reducing stress-related damage and promoting cell survival. SGs have become important players in human health, in addition to their fundamental role in the stress response. The critical role of SGs in cancer cells in formation, progression, and metastasis makes sense. Recent researchers have found that several SG components play a role in tumorigenesis and cancer metastasis via tumor-associated signaling pathways and other mechanisms. Gene-ontology analysis revealed the role of these protein components in the structure of SGs. Involvement in the translation process, regulation of mRNA stability, and action in both the cytoplasm and nucleus are among the main features of SG proteins. The present scoping review aimed to consider all studies on the effect of SGs on cancer formation, proliferation, and metastasis and performed based on a six-stage methodology structure and the PRISMA guideline. A systematic search of seven databases for qualified articles was conducted before July 2021. Publications were screened, and quantitative and qualitative analysis was performed on the extracted data. Go analysis was performed on seventy-one SGs protein components. Remarkably G3BP1, TIA1, TIAR, and YB1 have the largest share among the proteins considered in the studies. Altogether, this scoping review tries to demonstrate and provide a comprehensive summary of the role of SGs in the formation, progression, and metastasis of cancer by reviewing all studies.

show abstract

Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan

Cited by 14 publications

References 18 publications

Radioactive Iodine Treatment and the Risk of Long-Term Cardiovascular Morbidity and Mortality in Thyroid Cancer Patients: A Nationwide Cohort Study

Radioactive Iodine Treatment and the Risk of Long-Term Cardiovascular Morbidity and Mortality in Thyroid Cancer Patients: A Nationwide Cohort Study

Correlation between F18-FDG PET/CT Imaging and BRAF V600E Genetic Mutation for the Early Assessment of Treatment Response in Papillary Thyroid Cancers

Stress Granules Involved in Formation, Progression and Metastasis of Cancer: A Scoping Review

Contact Info

Product

Resources

About